FDA Grants Approval Status for Capecitabine ANDA204741 by Amneal Pharmaceuticals
The FDA has granted an approval status of 'AP' for Amneal Pharmaceuticals' ANDA204741 for Capecitabine.
Published: August 5, 2026
Updated: August 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy
Company: Amneal Pharmaceuticals
Asset: Capecitabine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Amneal Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval status for Amneal's ANDA204741 for Capecitabine is significant as it strengthens Amneal's competitive position in the oncology market. This development necessitates a review of market strategies for existing Capecitabine alternatives to mitigate potential market share loss.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the final approval and market launch timeline of ANDA204741.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.